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Abstract
Activated macrophages express a cell surface receptor for the
vitamin folic acid. Because this receptor is inaccessible or not
measurably expressed on other normal cells, folic acid has been
recently exploited to selectively deliver attached radio-emitters
to sites of activated macrophage accumulation, allowing
scintigraphic imaging of inflamed joints and organs of arthritic
rats. We demonstrate here that folate-linked haptens can also
be targeted to activated macrophages, decorating their cell
surfaces with highly immunogenic molecules. Under conditions
in which the rodent has already been immunized against keyhole
limpet hemocyanine-(fluorescein isothiocyanate) FITC, activated
macrophages are eliminated. Administration of folate-FITC
conjugates to rodents with experimental arthritis attenuates (a)
systemic and peri-articular inflammation, (b) bone and cartilage
degradation, and (c) arthritis-related body weight loss.
Treatment with folate-hapten conjugates is comparable to
methotrexate, etanercept, anakinra, and celecoxib at alleviating
the symptoms of arthritis. We conclude that reduction of
activated macrophages by folate-targeted immunotherapy can
ameliorate the symptoms of arthritis in two rodent models of the
disease.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by inflammation of the joints and destruction of carti-
lage and bone. Activated macrophages have been identified
as a key mediator of the disease, as numbers and level of mac-
rophage activation correlate with the extent of joint inflamma-
tion and bone degradation [1-4]. In addition, neutralization of
inflammatory mediators secreted by activated macrophages
suppresses symptoms of the disease [1-5].
Many therapies for RA are specifically designed to eliminate
pro-inflammatory byproducts of activated macrophages [6].
Remicade and etanercept neutralize tumor necrosis factor
alpha (TNF-α) [7-9], whereas anakinra blocks the activity of
interleukin (IL)-1 [8-10]. Celecoxib and Vioxx are inhibitors of
cyclooxygenase-2 [11], and anti-oxidants inactivate reactive
oxygen species. Yet some patients require other remedies,
either because of the ineffectiveness of the above therapies or
due to their associated toxicities [12,13].
Efforts have been made to eliminate the entire population of
macrophages [14-19], but elimination of all mononuclear
phagocytes can be harmful, because they are important in
fighting infectious diseases and promoting tissue repair
[20,21]. Thus, an attractive alternative to elimination of all mac-
rophages might be to remove only that subpopulation that pro-
motes RA (that is, the activated macrophage).
Activated macrophages from patients and rodents with arthri-
tis over-express a cell surface receptor for folic acid that also
AIA = adjuvant-induced arthritis; CIA = collagen-induced arthritis; CL = clodronate liposomes; FITC = fluorescein isothiocyanate; FR = folate recep-
tor; FTI = folate-targeted immunotherapy; HRP = horseradish peroxidase; Ig = immunoglobulin; IL = interleukin; KLH = keyhole limpet hemocyanine; 
MTX = methotrexate; PBS = phosphate-buffered saline; RA = rheumatoid arthritis; RAD score = radiographic score; TNF-α = tumor necrosis factor 
alpha.
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binds folate-linked compounds with high affinity (KD approxi-
mately 10-10 M) [22-24]. Recent studies have shown that
folate-linked radiopharmaceuticals concentrate in arthritic
joints, enabling visualization of such tissues by gamma scintig-
raphy [23-25]. We hypothesized therefore that selective
removal of activated macrophages with folate-linked drugs
could be exploited to treat RA with little toxicity to other tis-
sues. Here, we report a test of this strategy in two distinct
rodent animal models of the disease.
Materials and methods
Heat-killed Mycoplasma butyricum (BD Biosciences, Sparks,
MD, USA); light mineral oil, methotrexate (MTX), clodronate,
bovine serum albumin, keyhole limpet hemocyanine (KLH),
anti-rat immunoglobulin G (IgG)-horseradish peroxidase
(HRP), IgG-phycoerythrin conjugates, and alum (Sigma, St.
Louis, MO, USA); biotin-conjugated goat anti-rat IgG1, IgG2a,
and IgG (H+L), and streptavidin-conjugated HRP (Caltag Lab-
oratories, Burlingame, CA, USA); aminofluorescein (single iso-
mer) and fluorescein isothiocyanate (FITC) (Molecular Probes,
Eugene, OR, USA); Microcon-30 membranes (Millipore Corp.,
Bedford, MA, USA); TiterMax Gold® adjuvant (CytRx Corpora-
tion, Los Angeles, CA, USA); Celecoxib (Pfizer, Ann Arbor, MI,
USA); entanercept and anakinra (Amgen, Inc., Thousand
Oaks, CA, USA); EC20 (a folate-linked chelator of 99mTc) and
folate-FITC (Endocyte, Inc., West Lafayette, IN, USA) were
obtained from commercial sources. The studies were
approved by the Purdue University Animal Care and Use
Committee.
Induction and detection of anti-FITC antibodies
Anti-FITC antibodies were induced in rodent models with
experimental arthritis by vaccination with KLH-FITC (KLH-FITC
molar ratio of 1:13), using a modification of a published proce-
dure [26]. Rodents were immunized subcutaneously with an
emulsion of 150 µg KLH-FITC/200 µl adjuvant comprised of
either TiterMax Gold® (two injections each on days 0 and 28)
or Alum (three injections each on days 0, 14, and 28). Ten
days after the last boost, the serum was analyzed for anti-FITC
antibodies by enzyme-linked immunosorbent assay [26].
Induction and monitoring of experimental arthritis in 
rodents
Adjuvant-induced arthritis (AIA) was promoted in 200-g
female Lewis rats (Charles River Laboratories, Wilmington,
MA, USA) via either the footpad method [27] or the base-of-
tail method [8]. Collagen-induced arthritis (CIA) was initiated
in male DBA/1 LacJ mice (approximately 7 weeks old) (Chon-
drex, Inc., Redmond, WA, USA). The arthritic rodents were
weighed weekly. Arthritis scores were determined using a
weighted criterion (Chondrex, Inc.) and scored by a trained
investigator blinded to the treatment groups. When the arthri-
tis score reached 7, mice were randomly assigned to different
treatment groups. Rodents were maintained on a folate-defi-
cient diet (Harlan Tec) for 3 weeks prior to each study to lower
serum folate levels to their physiologic range (approximately
25 nM) [28].
Folate-targeted immunotherapy in experimental arthritis
Folate-FITC was administered i.p. to KLH-FITC-immunized
rodents according to the doses/schedules described in each
figure legend. For negative controls, KLH-FITC-immunized
rodents were treated with the non-targeted aminofluorescein,
which displays no affinity for folate receptors. Alternatively,
non-immunized rodents were treated with folate-FITC, which
binds readily to FR+ cells but cannot mediate anti-FITC anti-
body binding in the absence of KLH-FITC immunization.
Folate-targeted immunotherapy (FTI) was compared with
other therapies by treating AIA rats (base-of-tail method) 7
days after arthritis induction with one of the following: FTI
(KLH-FITC + Folate-FITC, 300 nmole/kg per day, i.p.), MTX
(0.75 mg/kg per week, i.p.) [29], celecoxib (20 mg/kg, oral
gavage every other day) [11], etanercept (4 mg/kg per day,
i.p.) [7-9], clodronate liposomes (3.6 mg/kg on days 8, 16, and
23, i.p.) [16], or anakinra (1.5 mg/kg per hour, continuous infu-
sion via subcutaneously implanted pump; Alzet, Cupertino,
CA, USA) [8-10].
Evaluation of therapeutic potencies
To determine whether FTI could ameliorate the symptoms of
experimental arthritis in rodent models, disease status was
assessed by monitoring changes in limb volume/ankle diame-
ter, radiological score (RAD score), and systemic inflamma-
tion. Limb volume was determined by calculating the product
of the measured length, width, and height of the limb (average
± SD, 8 rats/group). To determine the impact of the therapies
on bone/cartilage degradation, lateral radiographic projec-
tions of the tarsus of each rat were scored at the end of each
study. Radiographs were taken with direct exposure (1:1) on
un-screen KODAK X-OMAT TL film (Kodak, Rochester NY,
USA) using a Faxitron X-ray system with a 0.5-mm focal spot
and beryllium window (Faxitron X-ray Corporation, Wheeling,
IL, USA). Radiographs were scored by a board-certified veter-
inary radiologist blinded to the treatment groups. All radio-
graphs were evaluated by a board-certified radiologist without
knowledge of the assignment of treatment groups. RAD
scores were assigned according to a modification of a previ-
ously described method [27]. The radiographic changes were
graded numerically according to severity: increased soft tissue
volume (0–4), narrowing or widening of joint spaces (0–5),
subluxation (0–3), subchondral erosion (0–3), periosteal reac-
tion (0–4), osteolysis (0–4), and degenerative joint changes
(0–3).
Analysis of FR+ macrophages
To compare the abundance of macrophages in the ankle joints
of arthritic rats that were treated with FTI versus phosphate-
buffered saline (PBS), sections were analyzed by immunohis-
tochemistry for ED1 antigen using a protocol described previ-
ously [30]. Briefly, un-injected hind paws (ankle joint extending
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from the distal portion of the tibia to the medial metatarsals)
were fixed in 2% paraformaldehyde for 24 hours. They were
then washed with PBS overnight at 4°C and decalcified in
10% EDTA for 3 weeks at 4°C. After decalcification, speci-
mens were washed in PBS, and 10-µm thick sections were
cut serially with a cryostat. Sections were prepared from the
middle part of each ankle joint. A modified staining procedure
was used [30]. Sections were incubated with anti-ED1
(1:100; Serotec, Inc., Raleigh, NC, USA) in a humidified cham-
ber overnight (4°C) followed by peroxidase-conjugated sec-
ondary antibody (1:50, STAR72; Serotec, Inc.) for 1 hour at
room temperature. To determine whether other therapies
could also reduce the number of FR+ activated macrophages,
scintigraphy and the biodistribution of a folate-99mTc radioim-
aging agent (EC20) in relevant tissues were also evaluated
[23].
Figure 1
Folate-targeted immunotherapy (FTI) reduces activated macrophages systemically in adjuvant-induced arthritic (AIA) ratsI r  ti t  acr ha s syste ical y in adjuvant-induced arthritic (AIA) rats. (a) Treatment schedule for 
FTI. (b) The level of activated macrophages in internal organs (left) and limbs (right) of non-immunized arthritic rats (upper panel) and keyhole limpet 
hemocyanine-fluorescein isothiocyanate (KLH-FITC)-immunized arthritic rats (lower panel) 25 days after initiation of treatment with folate-FITC (375 
nmole/kg twice a week until day 21) was imaged 4 hours after i.p. injection of 0.5 mg EC20. (c) Activated macrophage accumulation in the liver and 
spleen was evaluated by measuring EC20 uptake in healthy non-arthritic rats (Healthy), AIA rats immunized with KLH-FITC and left untreated (KLH-
FITC), non-immunized rats injected i.p. with folate-FITC (375 nmole/kg twice a week), KLH-FITC-immunized AIA rats treated with folate-FITC (KLH-
FITC + Folate-FITC [FTI], 375 nmole/kg twice a week), and AIA rats injected with clodronate liposomes ([CL]; 3.6 mg/kg on days 8, 16, and 21, i.p.). 
EC20 biodistribution was measured by removal of the indicated tissues, weighing and counting them for radioactivity; represented as percent 
injected dose of EC20 per gram tissue, for instance, %ID EC20/g tissue (mean ± standard deviation, n = 5 rats/group). Data are representative of 
three independent experiments. (c) folate-FITC versus KLH-FITC + folate-FITC (FTI), p < 0.001.
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Analysis of the long-term toxicity of FTI
To obtain an indication of the toxicity associated with treat-
ment with FTI, KLH-FITC-immunized rats were injected three
times per week for 15 weeks with PBS or folate-FITC (300
nmole/kg). Four rats per group were sacrificed every 3 weeks,
and blood was analyzed for indicators of organ function (Ana-
lytics, Inc., Bethesda, MD, USA). Solid tissue samples were
obtained from each animal, and organs were examined histo-
logically for signs of tissue damage (Purdue Animal Disease
and Diagnostic Laboratory).
Splenomegaly
As documented elsewhere [27], one diagnostic characteristic
of systemic inflammation in AIA is a gradual increase in spleen
weight to more than twice its normal value. Therefore, to esti-
mate the impact of the various therapies on systemic inflamma-
tion, the weight of each animal's spleen was measured at the
end of each study.
Figure 2
Folate-targeted immunotherapy reduces folate receptor expressing macrophages in inflamed tissue of AIA rats
macrophages in inflamed tissue of AIA rats. (a) The level of folate 
receptor (FR)+ activated macrophages in the limbs of non-immunized 
(Folate-fluorescein isothiocyanate [FITC]) and keyhole limpet hemocya-
nine (KLH)-FITC-immunized AIA rats (KLH-FITC + Folate-FITC [FTI]) 25 
days after initiation of treatment with folate-FITC was determined 4 
hours after i.p. injection of 0.5 mg EC20. Folate-FITC was administered 
at 375 nmole/kg twice a week until day 23, and estimates of FR+ mac-
rophage numbers were made by weighing and counting the limbs for 
EC20 radioactivity (± standard deviation for n = 5 rats/group; [folate-
FITC] vs. [KLH-FITC + folate-FITC (FTI)], p < 0.001). (b) Histological 
analyses were conducted to obtain a visual assessment of the abun-
dance of ED1+ macrophages remaining in the inflamed soft joint tissue 
of the ankle joints (inflamed soft tissue adjacent to bone) of AIA rats 
immunized with KLH-FITC and then treated with either phosphate-buff-
ered saline (PBS) alone (KLH-FITC) or folate-FITC (KLH-FITC + Folate-
FITC [FTI]). Representative images from the joint tissue of two PBS-
treated and two folate-FITC (FTI)-treated rats are shown (n = 5 rats/
group).
Figure 3
Effect of folate-targeted immunotherapy on joint inflammation and bone/cartilag  destruction in AIA rats
bone/cartilage destruction in AIA rats. Where indicated, AIA rats were 
immunized with a 1:1 suspension of keyhole limpet hemocyanine-fluo-
rescein isothiocyanate (KLH-FITC) and TiterMax Gold adjuvant to gen-
erate a high anti-FITC antibody titer. On day 0, rats were induced to 
develop AIA via the footpad method. (a) Treatments began on the day 
of arthritis induction, and rats were given i.p. doses twice a week at 
375 nmole folate-FITC/kg. Treatment groups included: AIA rats not 
immunized and not treated (No Treatment), non-immunized rats treated 
with folate-FITC (Folate-FITC), AIA rats immunized against fluorescein 
and treated with non-targeted aminofluorescein (KLH-FITC + AF), AIA 
rats immunized against fluorescein and treated with folic acid alone 
(KLH-FITC + Folate), AIA rats immunized against fluorescein but not 
further treated (KLH-FITC), AIA rats immunized against fluorescein and 
treated with folate-FITC (KLH-FITC + folate-FITC [FTI]), AIA rats 
treated on days 8, 16, and 23 with 3.6 mg/kg clodronate liposomes 
(CL), AIA rats treated with methotrexate (MTX; 0.75 mg/kg per week, 
i.p.), immunized healthy rats (KLH-FITC + Healthy), and untreated 
healthy rats (Healthy), respectively. Data are representative of two inde-
pendent experiments (n = 5 rats/group; [folate-FITC] vs. [KLH-FITC + 
folate-FITC (FTI)], p < 0.01). The impact on bone and cartilage degra-
dation was assessed both by analysis of radiological (RAD) scores (b) 
and visual inspection (c) on day 25 after arthritis induction (mean ± 
standard deviation, n = 4 or 5 rats/group). Data are representative of 
three independent experiments. (RAD scores: folate-FITC vs. KLH-FITC 
+ folate-FITC (FTI), p < 0.05).
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Results
FTI reduces localized and systemic folate-binding 
macrophages
With the ability of folic acid to deliver attached imaging agents
specifically to activated macrophages in rodents with experi-
mental arthritis well established [23-25], the question naturally
arose whether therapeutic drugs might also benefit from FR-
specific targeting. Initial consideration of an appropriate drug
for delivery as a folate conjugate led to re-examination of strat-
egies already developed for the treatment of FR+ tumors. Thus,
it has been demonstrated that some cancer cells over-express
a folate receptor and that the surfaces of cancer cells can be
decorated with highly immunogenic haptens by targeting their
FRs with folate-hapten conjugates [26]. Under conditions in
which the rodent has already been immunized against the hap-
ten, hapten-decorated cancer cells rapidly bind anti-hapten
antibodies, resulting in their removal by FcR-expressing
immune cells. Given that folate-targeted haptens can lead to
eradication of FR+ tumors, it seemed logical to explore
whether a similar approach (Figure 1a) might be exploited to
reduce FR-expressing activated macrophages.
AIA was generated in Lewis rats by footpad injection of an oil
emulsion of heat-killed M. butyricum. Swelling of the injected
limb began immediately, whereas swelling of the non-injected
hind limb was more gradual, beginning approximately seven
days after injection and continuing unabated until euthanasia
became necessary. To determine whether FTI depletes folate-
binding macrophages in AIA rats, we quantitated the uptake of
a folate-linked chelate complex of 99mTc (termed EC20) that
was previously shown to be taken into activated macrophages
by FR-mediated endocytosis [23]. Because accessible folate
receptors are found in measurable numbers only on activated
macrophages [22], cancer cells [26], and the proximal tubule
cells of the kidneys [31], EC20 uptake in tumor-free liver,
spleen, lungs, intestines, and other organs is roughly propor-
tional to each organ's content of activated macrophages [23].
This uptake is visualized in both non-immunized and KLH-
FITC-immunized arthritic rats after identical treatment with
folate-FITC (Figure 1b). As evidenced from the γ-scintigraphic
images, uptake of the folate-99mTc complex (EC20) in spleen,
liver, kidneys, and limbs is substantial in non-immunized rats
treated with folate-FITC, but largely limited to the kidneys
(which ubiquitously express the FR on the apical surface of
their proximal tubules [31]) in KLH-FITC-immunized rats
treated with folate-FITC (FTI).
To visualize inflammation in the limbs of arthritic rats, mid- and
upper-body radiation was shielded with lead blankets and radi-
oimages of hind limbs were acquired by gamma scintigraphy.
As expected, uptake of the folate-targeted 99mTc agent
(EC20) in hind limbs was more intense in non-immunized than
in KLH-FITC-immunized AIA rats treated with folate-FITC (FTI)
(Figure 1b). Taken together, these results suggest that FTI
depletes activated macrophages both locally and systemically
in AIA rats.
To quantitatively assess the degree of systemic depletion of
activated macrophages by FTI, uptake of EC20 was analyzed
in the spleen and liver of AIA rats by scintillation counting.
EC20 content was approximately seven times greater in the
organs of both non-immunized rats treated with folate-FITC
and KLH-FITC-immunized rats left untreated than in healthy
rats or KLH-FITC-immunized animals treated with folate-FITC
(FTI) (Figure 1c; p < 0.001). Similar suppression of EC20
uptake was also observed in arthritic rats treated with clodro-
nate liposomes (CL), a bisphosphonate commonly used to
deplete all mononuclear phagocytes [23,25,30]. This latter
observation supports the contention that the EC20 uptake is
mediated by activated macrophages, as previously shown
[23,25]. Finally, FTI reduced AIA-induced spleen enlargement
twofold relative to untreated rats, suggesting that the immuno-
therapy reduces systemic inflammation.
Consistent with the decrease in EC20 uptake in the limbs of
AIA rats treated with FTI (KLH-FITC + folate-FITC) (Figures 1b
and 2a; p < 0.001), a considerable reduction of ED1+ (a mac-
rophage-specific marker) cells was also demonstrated by
immunohistochemical staining of the inflamed soft tissue of
the ankle joint of the FTI-treated rats (see representative micro-
graphs in Figure 2b). Taken together, the scintigraphic images,
EC20 uptake analyses, and immunohistochemistry demon-
strate that FTI reduces both systemic and articular accumula-
tion of folate-binding macrophages in arthritic rats.
FTI reduces bone and cartilage degradation and 
inflammation in limbs of AIA rats
In the footpad arthritis model, AIA rats immunized against fluo-
rescein (KLH-FITC) and then treated with folate-FITC (FTI)
experienced a >60% reduction in swelling of non-injected
limbs when compared with untreated arthritic rats (Figure 3a).
Evidence that the observed resolution of symptoms depended
on prior vaccination against fluorescein (KLH-FITC) was
obtained from controls that showed no therapeutic benefit
after treatment of non-immunized animals with folate-FITC
(solid diamonds). The requirement for folate targeting was
demonstrated by the fact that the therapy also failed when
KLH-FITC-immunized rats were left either untreated or treated
with non-targeted aminofluorescein (solid triangle). Finally, the
observation that folic acid alone exhibited no significant effect
on the KLH-FITC-immunized AIA rats (solid squares) argues
that the vitamin's targeting function, rather than its role in
metabolism, constitutes its major contribution to the immuno-
therapy. Importantly, this non-optimized FTI protocol reduced
inflammation in arthritic limbs with similar efficacy to CL and
MTX (Figure 3a).
By day 25 in AIA rats, histological analyses revealed multiple
symptoms of established arthritis, including cartilage and bone
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erosion, and massive macrophage infiltration. In KLH-FITC-
immunized AIA rats treated with folate-FITC (FTI), however, the
degree of cartilage and bone damage was markedly reduced
relative to that of KLH-FITC-immunized rats not treated with
folate-FITC (RAD scores: folate-FITC vs. KLH-FITC + folate-
FITC, p < 0.05) (Figure 3b,c). A similar protective effect was
observed in arthritic rats treated with MTX. Control studies fur-
ther confirmed that the FTI was both dependent on anti-FITC
antibody and FR-mediated, because no significant reduction
in bone score was seen in either non-immunized rats treated
with folate-FITC or in KLH-FITC-immunized rats left untreated.
FTI reduces inflammation and bone and cartilage 
degradation in limbs of CIA mice
Because therapeutic data in rodent models of arthritis can be
model-specific, the efficacy of FTI was also evaluated in estab-
lished CIA. All therapies were initiated seven days after onset
of CIA, when disease symptoms had already progressed to a
severe state. Visual inspection and arthritis scores (Figure
4a,b) revealed a marked reduction in inflammation after FTI.
Furthermore, bone damage was lower in KLH-FITC-immunized
mice treated with folate-FITC (FTI) than in similarly immunized
mice not treated with folate-FITC (Figure 4c), and uptake of
EC20 was also significantly lower in folate-FITC treated mice
than in non-treated mice (Figure 4d). Importantly, CIA mice
Figure 4
Effect of folate-targeted immunotherapy (FTI) on mice with established collagen-induced arthritisi i  t li  ll -i  rt riti . Mice were immunized with keyhole limpet hemocy-
anine-fluorescein isothiocyanate (KLH-FITC) in an equal volume of TiterMax Gold adjuvant to generate a high anti-FITC antibody titer. Seven days 
after arthritis induction, when the average arthritis score had reached 7, mice were treated daily with 600 nmole/kg folate-FITC until day 38. (a) Dif-
ferences between folate-FITC-treated and untreated mice were easily visualized. (b) Each limb was evaluated weekly by an individual blinded to the 
treatment groups and was assigned an arthritis score (see Methods and methods). (c) Bone erosion was analyzed on day 49 from radiographs by a 
radiologist blinded to the treatment groups. (d) Uptake of EC20 in both hind limbs was determined as a measure of activated macrophage accumu-
lation on day 49, represented as percent injected dose of EC20 per gram hind limbs, for instance, %ID EC20/g hind limbs. (e) The change in weight 
of mice after arthritis induction was measured regularly.
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treated with FTI did not lose weight whereas vaccinated mice
not treated with folate-FITC did (Figure 4e).
FTI is comparable to other common RA therapies
For comparison with the potencies of other common arthritis
therapies, a more stringent base-of-tail adjuvant-induced
arthritis model was used [8]. The disease was allowed to
develop 7 days prior to initiation of any therapy. Progression of
AIA was evaluated continuously by measuring ankle diameter.
Final disease status was assessed on day 42 by examining
radiographs for articular bone and cartilage degradation and
by determining EC20 uptake in macrophage-rich tissues. All
therapies were dosed according to the optimal schedule and
concentration reported by each manufacturer for use in
rodents (see Materials and methods).
Figure 5
Comparison of the effects of various arthritis therapies on disease severity n rats with established adjuv nt-induced arthritic (AIA)
severity in rats with established adjuvant-induced arthritic (AIA). Rats 
were left either unimmunized or immunized with keyhole limpet hemocy-
anine-fluorescein isothiocyanate (KLH-FITC) in an equal volume of alum 
adjuvant to generate a high anti-FITC antibody titer. AIA was induced 
by the base-of-tail method, and 7 days after induction each therapy was 
initiated. The therapies were folate-FITC in non-immunized rats (folate-
FITC; 30 nmole/kg per day, i.p.), non-targeted aminofluorescein (AF) in 
immunized rats (KLH-FITC + AF; 30 nmole/kg per day, i.p.), clodronate 
liposomes (CL; 3.6 mg/kg on days 8, 16, and 23, i.p.), celecoxib (20 
mg/kg every other day, oral gavage), etanercept (4 mg/kg per day, i.p), 
anakinra (120 mg/kg per day, continuous infusion, Alzet osmotic 
pump), methotrexate (MTX; 0.75 mg/kg per week, i.p.), or folate-tar-
geted immunotherapy (FTI) in immunized rats (KLH-FITC + folate-FITC 
[FTI]; 30 nmole/kg per day, i.p.). All groups were measured for arthritis 
symptoms by monitoring changes in ankle diameter (a), bone and carti-
lage degradation (b), uptake of EC20 in the spleen and liver (c), and 
splenomegaly (d). Data are representative of two independent experi-
ments (mean ± standard deviation, n = 5 rats/group).
Figure 6
No indication of toxicity was detected in rats treated with folate-tar-geted immu otherapy for 15 we ks
geted immunotherapy for 15 weeks. Toxicity analysis associated with 
continuous treatment of healthy keyhole limpet hemocyanine-fluores-
cein isothiocyanate (KLH-FITC)-immunized rats with folate-targeted 
immunotherapy (FTI) for 15 weeks. Non-immunized or KLH-FITC-immu-
nized rats were treated with folate-FITC (300 nmole/kg, three times per 
week) and sacrificed at the indicated times. Serum was analyzed for 
indicators of kidney (creatinine) (a) and liver (aspartate aminotrans-
ferase [AST-SGOT])(b) function. Tissue samples, including liver, kid-
ney, brain, lungs, and bone marrow, were simultaneously submitted for 
histopathological analyses. No indication of toxicity was detected by 
either type of analysis (tissue section data not shown) (mean ± stand-
ard deviation, n = 8 rats/group).
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AIA rats treated with FTI showed a reduction in ankle diameter
similar to that promoted by MTX, celecoxib, etanercept, anak-
inra, and CL (Figure 5a). Comparison of total bone scores
(Figure 5b) also suggested that FTI was competitive with other
therapies. Measurements of systemic inflammation, as indi-
cated by uptake of EC20 in the liver and spleen (Figure 5c)
and spleen enlargement (Figure 5d), further suggested that
FTI systemically reduces the numbers of activated macro-
phages at least as effectively as most commercial treatments.
In no case was the non-targeted aminofluorescein (KLH-FITC
+ AF) different from controls, reinforcing the need to target the
hapten to achieve a response.
FTI shows no signs of toxicity during 15 weeks of 
continuous treatment
To assess the long-term toxicity of FTI, both serum and tissues
from non-immunized and KLH-FITC-immunized healthy rats
treated three times per week for up to 15 weeks with folate-
FITC were evaluated by a commercial pathologist (Analytics,
Bethesda, MD, USA). Indicators of kidney (creatinine) and liver
(aspartate aminotransferase) function were within normal
ranges for the duration of the study (Figure 6). Also, no evi-
dence of either macroscopic or microscopic damage was
observed in any tissue-thin sections, including multiple sec-
tions of the liver, kidneys, brain, and other major tissues.
Discussion
We have explored a novel approach for the treatment of exper-
imental arthritis (the redirection of the immune system to
reduce endogenous activated macrophage, which is known to
be involved in maintenance of RA) [1-5,32-34]. Thus, ever
since it was observed that activated, but not resting, macro-
phages express a folate receptor [22], folate-linked drugs have
been found to specifically target arthritic joints and sites of
inflammation [23-25]. In this study, we have exploited folate's
targeting ability to selectively decorate activated macrophages
with immunogenic haptens that can mediate their removal in
immunized hosts. Prior vaccination against the hapten was
found to be necessary, because non-immunized animals did
not benefit from treatment with folate-FITC. Folate targeting of
the hapten was shown to be critical, because identical treat-
ment with non-targeted aminofluorescein was totally ineffec-
tive. Fluorescein derivatization was also found to be essential,
because administration of folic acid without an attached fluo-
rescein was equally impotent. In contrast, vaccination with
KLH-FITC followed by treatment with folate-FITC led to signif-
icant reduction in both local and systemic inflammation and to
measurable diminution in bone and cartilage degradation in
two advanced-stage models of RA.
We hypothesize that the efficacy of the FTI is related to its abil-
ity to promote systemic depletion of FR+ macrophages. As
noted above, activated macrophages constitute a likely
orchestrator of inflammation and joint destruction in experi-
mental arthritis [1-5,32-34]. Not only do activated macro-
phages release reactive oxygen species, collagenases,
cathepsins, and other mediators of joint destruction, but they
also recruit other immune cells by releasing pro-inflammatory
cytokines (TNF-α, IL-1, and IL-6), leukotrienes, and prostaglan-
dins [25]. Several investigators [22,23,25] have demonstrated
that activated macrophages express significant numbers of
cell-surface FR. Because folate-linked drugs bind avidly to
these receptors and localize to inflamed joints of animals and
humans with arthritis [23-25], it seems reasonable to posit that
their uptake at sites of inflammation might stem from their high
affinity for FR. Others have, in fact, established that synovial
macrophages from patients with RA aggressively bind folate-
FITC [22], and we have similarly demonstrated that folate-
FITC uptake in inflamed joints of rodents with experimental
arthritis occurs primarily in cells expressing both FR and mac-
rophage markers [23]. Because treatment of both CIA mice
and AIA rats leads directly to a significant reduction in folate-
binding macrophages, we speculate that painting of activated
macrophage cell surfaces with folate-FITC directly causes
their elimination in anti-FITC-immunized rodents by antibody-
dependent pathways. Studies are currently under way to test
this mechanism.
Comparative experiments revealed that FTI was as effective as
CL, MTX, etanercept, anakinra, and celecoxib at alleviating the
symptoms of experimental arthritis. Furthermore, FTI appeared
to be better than the above therapies at suppressing systemic
inflammation, as measured by both accumulation of EC20 in
liver and spleen and by reduction of inflammation-mediated
spleen enlargement. This capability to reduce systemic inflam-
mation may be important, because patients with RA have a
reduced life expectancy that is caused by systemic, rather than
articular, inflammation [35].
An attractive feature of the FTI approach lies in its apparent
lack of toxicity. Because FRs are also expressed on the apical
surfaces of a few normal epithelia (for example, the choroid
plexus of the brain, bronchioalveolar cells of the lungs, and
proximal tubules of the kidney), it might have been anticipated
that immune responses would have been elicited against
these tissues also. However, fluorescence micrographs show
that sites of FR expression on normal epithelia are inaccessi-
ble to circulating antibodies [31], because the receptor invari-
ably resides on the apical surface of the epithelium where it
faces a lumen that is usually inaccessible to parenterally
administered drugs. Thus, pathological analyses have not
revealed any cytotoxicity or immune damage to normal tissues.
One concern that must accompany systemic depletion of acti-
vated macrophages relates to the possible decline in defense
against pathogens. Although no infections/diseases were
observed in rats maintained on the therapy for 15 continuous
weeks, nor in RA dogs treated for more than 2.5 years (Paulos
CP, Varghese B, Vlashi E, Low PS, Widmer WR, and Breur
GJ), unpublished observations), sufficient time has not yet
Available online http://arthritis-research.com/content/8/3/R77
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elapsed to conclude that long-term defects will not emerge
during continuous treatment. Although resting macrophages
and other immune cells might compensate for elimination of
most activated macrophages, it will be important to examine
chronically treated animals for deficiencies in tasks normally
performed by activated macrophages. Where temporary defi-
ciencies do arise, it might be sufficient to remove the patient
from the therapy until the deficiency subsides.
A second potential concern might arise from the possible for-
mation of multimeric immune complexes in circulation after
injection of the folate-hapten conjugate. However, because
folate-FITC contains only one antibody-binding site, it cannot
mediate formation of multimeric immune complexes, even
though monomeric IgG-folate-FITC complexes are readily
observed in circulation. Thus, deposition of macroscopic
immune complexes in non-targeted tissues has not consti-
tuted a source of observed toxicity.
Conclusion
In summary, we have demonstrated that removal of folate-bind-
ing macrophages suppresses established arthritis in two ani-
mal models of the disease. Because little measurable toxicity
accompanied the therapy, these data suggest that removal or
inactivation of folate receptor-expressing macrophages might
constitute an alternate approach for treatment of the pathol-
ogy. Thus, in addition to the existing pantheon of drugs aimed
at neutralizing secretion products of activated macrophages
(that is, Remicade, Enbrel, Humira, Kineret, Vioxx, Celebrex,
and so on), examination of folate-targeted drugs that can block
the inflammatory activity of the same cell type would seem to
warrant further scrutiny [25].
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